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Abstract 
Background: Caffeine is commonly consumed during pregnancy, crosses the placenta, with 
fetal serum concentrations similar to the mother’s, but studies of birth outcome show 
conflicting findings. 
Methods:  We systematically searched Medline and Embase for relevant publications. We 
conducted meta-analysis of dose-response curves for associations between caffeine intake 
and spontaneous abortion, stillbirth, preterm delivery, low birth weight and small for 
gestational age (SGA) infants. 
Results: Meta-analyses included 60 unique publications from 53 cohort and case-control 
studies. An increment of 100g caffeine was associated with a 14% (95% CI: 10 to 19%) 
increase in risk of spontaneous abortion, 19% (5 to 35%) stillbirth, 2% (-2 to 6%) preterm 
delivery, 7% (1 to 12%) low birth weight, and 10% (95%CI: 6 to 14%) SGA. There was 
substantial heterogeneity in all models, partly explained by adjustment for smoking and 
previous obstetric history, but not by prospective assessment of caffeine intake. There was 
evidence of small-study effects such as publication bias. 
Conclusion: Greater caffeine intake is associated with an increase in spontaneous abortion, 
stillbirth, low birth weight, and SGA, but not preterm delivery. There is no identifiable 
threshold below which the associations are not apparent, but the size of the associations are 
generally modest within the range of usual intake and are potentially explained by bias in 
study design or publication. There is therefore insufficient evidence to support further 
reductions in the maximum recommended intake of caffeine, but maintenance of current 
recommendations is a wise precaution. 
 
Keywords: Caffeine; pregnancy; miscarriage; stillbirth; preterm birth; birth weight; small for 
gestational age infant; meta-analysis  
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Introduction 
Caffeine is present in many drinks and foods consumed during pregnancy, most notably in 
tea, coffee, colas, energy drinks and chocolate. Although amounts vary due to brand and 
brewing methods, and vary from country to country, on average one 260ml (10oz) mug of 
coffee contains around 100mg caffeine. It is also a constituent of several common 
medications available over the counter or on prescription [1]. Given its widespread presence, 
most pregnant women consume at least small amounts. However, its effects on the 
developing fetus are still not fully understood [2]. 
 
Animal studies suggest possible adverse effects on reproductive outcomes, including fetal 
growth, but may not be relevant for humans because caffeine metabolism varies greatly 
across species [2;3]. In humans, studies have reached mixed conclusions, in part because of 
difficulties measuring caffeine intake, but also because of other clinical influences on fetal 
growth and birth outcomes [4-6]. Only one randomised controlled trial of caffeine reduction 
during pregnancy has been conducted to date, concluding that “moderate reductions” in 
caffeine intake (of around 200mg) do not substantially alter birthweight or length of gestation 
[7]. Given that the intervention came after the 1st trimester, did not investigate the more 
important outcome of spontaneous abortion, and only intervened on one source of caffeine 
(coffee), questions over the safe consumption of caffeine in pregnancy remain.  
 
Because of the possible associations with restricted fetal growth, birth defects, miscarriage 
and stillbirth in humans, guidance in several countries, including the US and UK, has 
continued to consider it a wise precaution to limit caffeine intake to less than 200mg 
immediately before and during pregnancy [2;8-10]. In the UK, guidance has recently changed 
to reduce the recommended maximum intakes to this level [11]. However, because of the 
differing conclusions reached by several major studies, the strength of any association, and 
the possibility of a threshold effect, has not been fully quantified [2;8;12]. 
 
To inform guidance, and in the light of recent large prospective studies, we aimed to pool 
information from the different observational studies that present information on the 
association between caffeine and the adverse birth outcomes of spontaneous abortion, 
stillbirth, preterm birth, low birth weight and small for gestational age. We aimed to avoid 
problems present in many systematic reviews of observational studies that compare extreme 
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categories by estimating the dose-response slope over all categories of intake [13]. In 
particular, we aimed to quantify the degree of any association and identify any possible 
threshold effects through modelling nonlinear dose-response curves. 
 
Methods 
Data sources and searches 
We conducted a comprehensive systematic literature search covering all case-control and 
cohort studies providing evidence on dietary caffeine intake and adverse pregnancy 
outcomes, including spontaneous abortion or miscarriage, stillbirth, preterm birth, low birth 
weight and small for gestational age (SGA) infants. We searched MEDLINE and EMBASE 
online databases for all studies published in any language up to 15th May 2014 (detailed 
search strategy in online table 1). We also hand searched the reference lists of included 
studies and relevant review articles. The guidelines for conducting meta-analysis of 
observational studies in epidemiology were used throughout the design, conduct, analysis, 
and reporting of this review [14]. A detailed protocol for this review was produced, but is not 
yet available to download. Instead, methods are provided in detail in this paper. 
 
Study selection 
We screened titles and abstracts to remove publications when it was immediately apparent 
they were not relevant, such as editorials and single case-study reports. We obtained full-text 
versions of potentially relevant articles. The process of identifying relevant articles was 
conducted independently by five members of the review team (DCG, JY, LG, GK, LGK). 
The first author made the final decision where there were any differences. Only case-control 
and cohort studies were eligible for inclusion in the review, including nested case-control and 
case-cohort studies.  
 
Inclusion criteria were studies based on dietary assessment of maternal caffeine intake during 
pregnancy (not before), published in any language, with assessment of caffeine or coffee with 
more than two categories of exposure, with outcomes including at least one of spontaneous 
abortion (fetal loss under 24 weeks gestation or less), stillbirth (fetal loss after 24 weeks 
gestation), preterm birth (before 37 weeks), low birth weight (less than 2500g), or small for 
gestational age infant (defined as a weight below the 10th percentile for a given gestational 
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age), as an outcome. Studies had to include some estimate of relative risk (RR) with a 
measure of uncertainty such as 95% CIs.  
 
Where results from the same study were presented in several papers, the results based on the 
larger sample, with the most complete assessment of caffeine intake (i.e. total caffeine rather 
than just caffeine from coffee), or that with the most appropriate adjustment for confounding, 
were used. 
 
Where caffeine-containing beverages were not presented as mg of caffeine per day, a serving 
of coffee was assumed to contain approximately 100mg caffeine and any caffeine-containing 
beverage not separated into different sources (e.g. coffee, tea or cola) was assumed to contain 
60mg of caffeine on average [15]. These are broadly in line with the assumptions made in the 
studies included that assessed caffeine intake on the basis of dietary intake. 
 
To be included in linear dose–response meta-analyses, studies needed to present estimates of 
RR with associated CIs for at least three categories of intake, alongside a quantified measure 
of caffeine or coffee intake, with sufficient detail regarding the numbers of cases and non-
cases. Studies already presenting results as linear dose-response (e.g. relative risk per 
100mg/day) were included as well. Where studies presented results in both ways, the latter 
was taken as being the most accurate. To be included in nonlinear dose-response meta-
analyses, more than three categories of intake were required, and results presented only as 
linear dose-response curves could not be used. 
 
Data extraction and quality assessment 
From the publications identified, we extracted the following information: authors, publication 
year, geographical region of the study, numbers of cases and non-cases, whether dietary 
assessment was prospective (before delivery) or retrospective, whether assessment of caffeine 
was based on multiple dietary sources or just coffee, level of dietary exposure (either as 
mean, median, midpoint or range for each category or unit of increment for continuous 
estimates), estimated relative risks with confidence intervals, and characteristics controlled 
for either by modelling, matching or stratification. Data extraction was carried out by YJ and 
DCG and its accuracy checked by DCG and a sample by JC. 
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We assessed the methodological quality of studies using the Newcastle-Ottowa scale for 
either case-control or cohort studies, as appropriate, presented as a risk of bias table [16]. For 
cohorts, stars were awarded in the “selection” category for participants being representative 
pregnancies in terms of caffeine intake, sampling of unexposed participants from the same 
community, detailed caffeine assessment, and demonstration that adverse pregnancy 
outcomes were not present at the start of the study. Comparability stars were awarded for 
adjustment for age and for smoking. These should be interpreted as risk of bias in the 
estimate, and not the study itself, as some estimates were derived from unadjusted descriptive 
statistics of secondary exposures. Outcome stars were awarded for outcomes based on 
medical records rather than self-report, for follow-up to end of pregnancy, and for at least 
70% follow-up. For case-control studies, stars were awarded for similar criteria, selection 
stars being awarded for independently validated cases, cases representative of all incident 
adverse outcomes, appropriately sourced controls, and controls demonstrably free from the 
adverse outcome. Comparability stars were awarded as for cohorts. For case-control studies, 
the remaining quality assessment is based on the exposure definition rather than the outcome 
definition, with exposure stars awarded for caffeine assessment blind to case-control 
outcome, the same method of caffeine assessment for cases and controls, and the same 
response rate in both groups (within 10 percentage points of each other). All studies were 
included, regardless of perceived quality. 
 
Data synthesis and analysis 
So that we could legitimately pool results from studies using different exposure 
categorisation, we derived a linear dose-response trend for each study using Greenland and 
Longnecker’s method [17]. This method allows estimation of study-specific linear dose-
response slopes and their associated confidence intervals, based on the results presented for 
each category of caffeine intake. These dose-response slopes, now all representing estimates 
of the same quantity, can then be combined into an overall pooled estimate using standard 
methods for meta-analysis. 
 
So that we could derive the dose-response trend, we used the mean or median caffeine intake 
for each category if this was presented. We used the category midpoints when caffeine intake 
was only reported as a range. When the highest or lowest categories of intake were 
unbounded, we estimated the midpoint by assuming the width of the category was the same 
as the next adjacent category. If the distribution of cases was not presented in the publication, 
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we estimated these initial numbers from definitions of the quantiles, assuming equal numbers 
in each category.  
 
When studies already presented a linear dose-response trend based on a continuous measure 
of caffeine intake, alongside a measure of precision such as a confidence interval or a 
standard error, then we used this instead of deriving the trend indirectly. Where results were 
presented for two distinctly separate subgroups of women[18], we combined the separate 
subgroup results first using a fixed effects meta-analysis before they were combined with the 
other studies. In this way the between-study heterogeneity was estimated appropriately. 
Where results were presented for two distinct sub-outcomes on the same women [19], these 
were first combined using an approach suggested by Hamling et al. [20]. This combines the 
fitted cell counts for the two sub-outcomes, maintaining the same exposure category totals, 
combining the two results into one with no double counting. We then pooled all the estimated 
dose-response trends for each study using a random effects model that takes into account the 
anticipated between-study heterogeneity [21]. 
 
We also explored potential nonlinear associations between caffeine and birth outcome. For 
each study that presented results for more than three categories of intake (the minimum 
required to model a nonlinear curve) we calculated a restricted cubic spline. This was based 
on three knots fixed at 10%, 50% and 90% through the total distribution of intake [22]. We 
then combined these using multivariate meta-analysis [23]. 
 
We quantified the percentage of total variation in study estimates attributable to between-
study heterogeneity (I
2
) and tested between-study heterogeneity using Cochran’s Q [24]. We 
assessed the methodological quality of studies using the Newcastle-Ottowa scale, presented 
as a risk of bias table. We also performed a limited number of pre-defined subgroup analyses 
to explore aspects of study quality that may have contributed to the differences in the results 
seen across the studies, such as retrospective or prospective assessment of intake, source of 
caffeine, geographic location, and adjustment for pre-specified potential confounders. 
Though caffeine metabolism may be moderated by CYP1A2 activity, smoking status, or 
nausea [25], numbers of studies reporting stratified analyses were too few to enable 
investigation of effect modification by these factors. We conducted sensitivity analysis 
excluding potentially highly influential studies and studies that might be considered 
materially different. Any such analyses are included in the relevant section of the results. We 
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investigated potential small study effects, such as publication bias, using contour-enhanced 
funnel plots. However, with small numbers of included studies, exploration of sources of 
heterogeneity and of small study effects lacked power. All analyses were conducted using 
Stata version 13.1 [26]. 
 
Results 
Literature search 
 
In total, 91 relevant publications were identified, of which 14 contained replicated 
information, and 17 did not contain sufficient information for inclusion in the meta-analyses 
(figure 1). This left 60 unique publications from 53 studies (26 cohort and 27 case-control) 
with sufficient information for inclusion in dose-response meta-analyses. Of these 53 studies, 
29 were from the US, 21 from Europe, 2 from South America, and 1 from Cuba. 
Characteristics of the included studies are shown in online tables 2a to 2e alongside an 
assessment of risk of bias for each study. 
 
One publication only presented miscarriage combined with stillbirth [27]. These two 
outcomes could have very different risk factors, but because of the low incidence of stillbirth 
relative to miscarriage, this publication was included in the meta-analysis of miscarriage, 
with sensitivity analysis to confirm this did not materially influence the pooled estimate. One 
study of low birth weight also included some small for gestational age infants [28]. This was 
included in the low birth weight analysis as these formed the majority of events, but with 
sensitivity analysis to confirm that this did not substantially change the results. One study 
provided additional information on miscarriage and stillbirth separately that was incorporated 
into the meta-analyses [29]. One publication provided results for the association between 
preterm delivery and caffeine separately for small for gestational age infants and normal for 
gestational age infants [18]. These two subgroups were first combined using a fixed effects 
meta-analysis before they were pooled with the other studies. One study presented the 
association between caffeine and preterm delivery with premature rupture of the membranes 
separately from those without premature rupture of the membranes [19]. These were first 
combined using an approach suggested by Hamling et al. [20] before pooling with the other 
studies. One publication was based on women with type 1 diabetes [30]. Because of the non-
general population, a sensitivity analysis was conducted to confirm that this did not 
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materially influence the pooled estimate. Where a publication presented results for different 
definitions of small for gestational age, the method most consistent with the other studies was 
used [31]. However, one publication with a combined outcome of ultrasound-based diagosis 
of intrauterine growth restriction and low birth weight, could not be included in either 
category [32]. 
 
Miscarriage 
 
Our literature search identified 35 unique publications from 32 studies investigating the 
association between caffeine and miscarriage. Data were extracted from 26 of these studies 
(14 cohort, 12 case-control), 13 from Europe and 13 from the US. The pooled estimate of 
relative risk from linear dose–response meta-analysis was 1.14 (95% CI: 1.10 to 1.19) per 
100 mg/day of caffeine (P < .001) (figure 2A). Five of the six studies that could not be 
included in meta-analyses supported this direction of association, with all but one statistically 
significant [33-37], and the remaining study finding no evidence of any association [38]. 
 
There was substantial heterogeneity between the studies (I
2
 = 89%; 95% CI: 85 to 92%; Q = 
230; df = 25; P < .001). The estimated between-study variance was unchanged by excluding 
the study that had combined miscarriage and stillbirth into a single outcome [27], and this 
resulted in a negligible change to the pooled estimate (RR = 1.14; 95% CI: 1.09 to 1.18; P < 
.001). Excluding the study with greatest influence [39] decreased the estimated between-
study variance by more than half, but resulted in only a marginally reduced estimate (RR = 
1.11; 95% CI: 1.07 to 1.14; P < .001), so was subsequently excluded from the subgroup 
analyses.  
 
There was no evidence that any study characteristics investigated, such as retrospective 
caffeine assessment or adjustment for specific potential confounders, were associated with 
higher or lower estimates in subgroup analyses (online table 3a). However, there was 
evidence of considerable asymmetry in the funnel plot (online figure 1a), to the extent that 
small-study effects such as publication bias cannot be ruled out for this outcome.  
 
The nonlinear dose–response meta-analysis showed a small but consistently increasing 
incidence of miscarriage associated with increased daily caffeine intake (figure 2B). There 
was little evidence of any nonlinear association, such as a threshold effect, in the plot. 
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Stillbirth 
Our literature search identified 8 unique publications from 5 studies investigating the 
association between caffeine and stillbirth. Data were extracted from all 5 of these studies (3 
cohort, 2 case-control), 3 from Europe, 1 from the US and 1 from Uruguay. The pooled 
estimate of relative risk from linear dose–response meta-analysis was 1.19 (95% CI: 1.05 to 
1.35) per 100 mg/day of caffeine (P = .007) (figure 2C). All the identified studies were 
included in meta-analyses. 
 
There was substantial heterogeneity between the studies (I
2
 = 82%; 95% CI: 59 to 92%; Q = 
22; df = 4; P < .001). Studies that only considered coffee had substantially lower estimates 
than those that considered caffeine from multiple sources (P = .02). Stratifying on this study 
characteristic reduced the percentage of total variation in estimates attributable to between-
study heterogeneity to less than 50% in both groups (online table 3b).  Again there was 
evidence of asymmetry in the funnel plot (online figure 1b), but the number of studies was 
small.  
 
The nonlinear dose–response meta-analysis showed a small but consistently increasing 
incidence of stillbirth associated with increased daily caffeine intake (figure 2D). There was 
little evidence of any nonlinear association. 
 
Preterm delivery 
The literature search identified 21 unique publications from 20 studies investigating the 
association between caffeine and preterm delivery. Data were extracted from 15 of these 
studies (8 cohort, 7 case-control), 6 from Europe and 9 from the US. The pooled estimate of 
relative risk from linear dose–response meta-analysis was 1.02 (95% CI: 0.98 to 1.06) per 
100 mg/day of caffeine (P = .42) (figure 2E). Of the five studies that could not be included in 
meta-analyses, four suggested some positive association [40-43], and one did not [44]. 
 
There was substantial heterogeneity between the studies (I
2
 = 63%; 95% CI: 34 to 79%; Q = 
38; df = 14; P = .001). Studies with prospective dietary assessment of caffeine intake tended 
to have more positive associations with preterm delivery than those with retrospective 
assessment (P = .04) (online table 3c). There was no evidence of any asymmetry in the funnel 
plot (online figure 1c).  
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The nonlinear dose–response meta-analysis showed a generally straight flat line with no 
evidence of any nonlinear association (figure 2F). 
 
Low birth weight 
We identified 14 unique publications from 14 studies investigating the association between 
caffeine and low birth weight. Data were extracted from 11 of these studies (6 cohort, 5 case-
control), 3 from Europe, 7 from the US and 1 from Brazil. The pooled estimate of relative 
risk from linear dose–response meta-analysis was 1.07 (95% CI: 1.01 to 1.12) per 100 
mg/day of caffeine (P = .01) (figure 3A). Of the three studies not included in meta-analysis, 
one found a strong association between caffeine and low birth weight [45], whilst the other 
two found no evidence of any association [40;46]. 
 
There was substantial heterogeneity between the studies (I
2
 = 75%; 95% CI: 55 to 86%; Q = 
40; df = 10; P < .001). Excluding the study with additional small for gestational age infants 
[28], had a negligible impact on the pooled estimate or the estimated heterogeneity (RR = 
1.06; 95% CI: 1.01 to 1.12; P = .02). Studies that adjusted for maternal education or socio-
economic factors had substantially lower estimates than those that did not (P = .02) (online 
table 3d). There was some evidence of asymmetry in the funnel plot (online figure 1d), 
leaving open the possibility of small-study effects such as publication bias.  
 
The nonlinear dose–response meta-analysis showed a small but consistently increasing 
incidence of low birth weight associated with increased daily caffeine intake (figure 3B). 
There was little evidence of any nonlinear association. 
 
Small for gestational age 
A total of 18 unique publications were identified investigating the association between 
caffeine and small for gestational age infants, based on 18 studies. Data were extracted from 
15 studies (10 cohort, 5 case-control) that could be included in meta-analysis, 6 from Europe 
and 9 from the US. The pooled estimate of relative risk from linear dose–response meta-
analysis was 1.10 (95% CI: 1.06 to 1.14) per 100 mg/day of caffeine (P < .001) (figure 3C). 
The three studies that could not be included in meta-analysis provided mixed results, with 
one suggesting an association [47], one not [40], and a third suggesting no overall 
association, but some evidence of effect modification by smoking [48]. 
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There was substantial heterogeneity between the studies (I
2
 = 64%; 95% CI: 38 to 80%; Q = 
39; df = 14; P < .001). Studies that adjusted for smoking (P = .04) and studies that adjusted 
for previous adverse pregnancy outcomes (P = .05) tended to have lower estimates than those 
that did not adjust for these potential confounders (online table 3e). There was some evidence 
of asymmetry in the funnel plot (online figure 1e), leaving open the possibility of small-study 
effects such as publication bias. 
 
The nonlinear dose–response meta-analysis showed a small but consistently increasing 
incidence of small for gestational age infants associated with increased daily caffeine intake 
(figure 3D). There was little evidence of any nonlinear association. 
 
Discussion 
We have, for the first time, quantified with precision the association between caffeine and 
adverse birth outcomes, based on 60 publications from 53 separate cohort and case-control 
studies of adverse pregnancy outcomes. Meta-analysis of the associations between caffeine 
intake contain nearly 15000 cases of miscarriage from 180000 women, 700 still births from 
120000 women, 8000 preterm deliveries from nearly 110000 women, 5000 low birth weight 
infants from nearly 78000 women, and nearly 12000 small for gestational age infants from 
160000 women. The evidence covers a variety of countries with different levels of intake, 
including non-consumers and categories consuming over 1000 mg/day. This pooled evidence 
allows the associations between caffeine intake during pregnancy and these adverse outcomes 
to be described in greater detail than previously possible, and in a manner that allows the 
shape of the dose-response curve to be described. 
 
A small but quantifiable association was observed between caffeine intake during pregnancy 
and incidence of miscarriage, stillbirth and low birth weight. There is also a similar sized 
association between caffeine intake during pregnancy and small for gestational age. There 
was no evidence of an association between caffeine intake and preterm delivery. For all 
outcomes the dose-response curves are fairly linear, with no evidence of any “threshold 
effect” or “plateau” in the dose-response curves. Heterogeneity is generally high, with little 
between-study heterogeneity being explained by aspects of study design or analysis 
investigated. 
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The size of the associations are relatively modest within the range of intakes consumed by the 
majority of women in the included studies, and within the range of intake currently 
recommended in most countries during pregnancy. In addition, the size of the associations are 
small relative to some established risk factors such as maternal smoking, but similar to others 
such secondhand smoke [49]. It is therefore important to interpret any public health 
implications regarding caffeine intake in the context of known lifestyle risk factors.  
 
It is also important to interpret these results alongside the clinical implications of the 
outcomes. Whilst the consequences of small for gestational age infants are less severe than 
miscarriage or stillbirth, small for gestational age has been associated with an increased risk 
of perinatal mortality and morbidity, including perinatal asphyxia. There is also a body of 
literature suggesting that it is associated with adverse effects in adult life [50;51], such as 
increased incidence of obesity, hypertension, hypercholesterolemia, cardiovascular disease, 
and type 2 diabetes [52-54], If shown to be causal, a small association could therefore still be 
of importance from a public health perspective. 
 
Given the observational nature of the evidence, we cannot draw inferences on the causal 
nature of the association identified in this review. Meta-analyses of observational studies are 
prone to the same biases as the studies they pool evidence across. Therefore the evidence 
from case-control studies are particularly susceptible to selection bias and recall bias, and all 
the studies are susceptible to uncontrolled confounding. In addition, all these observational 
studies are liable to bias from measurement error in using self-report measures to estimate the 
dietary intake of caffeine. One particular issue common to the majority of studies was the 
lack of an objective measure of exposure to tobacco smoke. Smoking is a potentially very 
strong confounder: smokers both consume more caffeine than non-smokers (because 
smokers’ altered CYP1A2 activity leads to faster caffeine clearance) and have much higher 
rates of adverse birth outcomes [55]. It is therefore important to measure smoking 
objectively, using a repeated biomarker such as cotinine, to avoid measurement error bias, 
which in this case could lead to exaggerated associations from only partially controlling for 
its confounding effects [56]. 
 
The large heterogeneity observed in the meta-analyses also requires caution to be exercised in 
the interpretation of the results. Whilst earlier meta-analyses have also observed substantial 
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heterogeneity [4;5;57], these may be explained in part by their pooling studies using different 
categories of intake. We tried to avoid this by placing each study on the same scale, pooling 
dose-response trends instead [13]. Beyond this, we investigated other potential sources of 
heterogeneity through a small number of a subgroup analyses specified in advance. We used 
this to explore whether different study characteristics were associated with the observed 
differences in the results. These included study design, the method of caffeine intake 
assessment and adjustment for pre-specified potential confounders such as smoking. Whilst 
each of these were associated with some of the heterogeneity, it was not consistent across the 
outcome groups. Though heterogeneity was generally high, it mostly reflected variation in the 
size of the association, rather than whether there was an association. Heterogeneity associated 
with small-study effects such as publication bias was also observed for the meta-analyses of 
miscarriage, stillbirth, low birth weight and small for gestational age. 
 
It is possible that reduction in caffeine may be a marker for a healthier pregnancy and that 
caffeine is not the cause of the adverse outcomes [58;59]. None of the studies reviewed in 
this paper have adequately addressed this issue; simply adjusting for nausea does not correct 
for this potential bias and subgroup analysis suggested it made little difference to the 
estimates. This potential bias therefore remains the most prominent argument against a causal 
role of caffeine. Neither are pragmatic trials immune to this potential bias, where greater 
compliance with the intervention may be associated with healthier pregnancy. 
 
Only one large double-blind randomised controlled trial of caffeine reduction during 
pregnancy and subsequent birthweight has been conducted to date [7]. Over one thousand 
Danish women were recruited, each consuming over three cups of coffee a day, and 
randomised to either caffeinated or decaffeinated coffee. However, the trial did not assess the 
important outcomes of miscarriage or stillbirth, ignored caffeine intake during the first 
trimester when caffeine consumption changes markedly and the majority of fetal deaths occur 
[7;60], and did not measure compliance through objective biomarkers of caffeine intake. In 
addition, the intervention focussed on coffee intake rather than caffeine as a whole, whilst 
there is evidence from other countries that cola drinks, tea and chocolate may all contribute at 
least as much caffeine to the diet during pregnancy [6;60]. These features of the trial limit the 
extent to which its results can contribute towards discussion of caffeine intake as a whole, or 
the association with miscarriage and stillbirth. In the absence of any other substantive trial 
data, our meta-analysis of observational studies provides a valuable resource. 
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If the observed association is causal, it is possible that it may be due to caffeine itself, to one 
of its metabolites, or a combination of them. Of the four primary routes of caffeine 
metabolism in humans, 3-demethylation is quantitatively the most important, the caffeine 
being converted to paraxanthine by CYP1A2. Studies have shown there to be varying levels 
of CYP1A2 activity in humans and there is considerable inter-individual variation in caffeine 
metabolism [61]. Measures of caffeine consumption therefore do not necessarily indicate the 
levels of caffeine and caffeine metabolites in the maternal or fetal circulation. A small 
number of studies have measured levels of caffeine and its metabolites in maternal or 
umbilical cord blood rather than assessing caffeine consumption [55;62;63], though given the 
range of possible exposures, this was not the focus of this review. Linking phenotype with 
genotype is, however, an area for possible future research. 
 
Given the observational nature of the studies, the heterogeneity and small-study effects, it is 
not possible to conclude that these associations are causal. The modest sizes of the 
associations are such that it is possible they could be explained by any or all of these potential 
biases. However, the plausible biological mechanisms, the evidence from animal studies, the 
mounting evidence from different observational human studies, and the dose-response slopes, 
provide some evidence to support the current recommendations limiting caffeine intake 
during pregnancy, such as restricting to less than 200 mg/day, as a precaution in case the 
associations really are causal. Whilst the associations are modest in size, they are potentially 
important at a public health level, and for infants already at elevated risk of adverse 
outcomes.  
 
In summary, combining results from a large number of studies has allowed associations 
between caffeine intake and adverse pregnancy outcomes to be quantified with precision and 
discern a modest but significant association with caffeine intake that could only be 
adequately quantified by pooling results. A number of questions still remain to be answered. 
These include confirming causality, such as identifying whether caffeine is the causal agent, 
one of its metabolites, or whether the associations are completely explained by publication 
bias or caffeine being a marker of healthy pregnancy. Whilst these issues are unresolved, our 
results confirm the precautionary guidance adopted by countries recommending limiting 
caffeine consumption during pregnancy. 
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Figure 1. Article retrieval and screening process flow chart. 
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Figure 2. Dietary caffeine intake and estimated relative risk of miscarriage, stillbirth, and preterm birth.  
A,C,E: Forest plots of linear dose–response trends with pooled estimates from random-effects meta-analysis per 100mg/day caffeine intake for 
miscarriage (A), stillbirth (C), and preterm birth (E). B,D,F: Summary nonlinear dose–response curves from multivariate random effects meta-
analysis of restricted cubic spline curves for miscarriage (B), stillbirth (D), and preterm birth (F), using zero intake as the reference intake. 
Tickmarks on the horizontal axis indicate the location of category medians, means, or midpoints for included studies. 
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Figure 3. Dietary caffeine intake and estimated relative risk of low birth weight and small for gestational age.  
A,C: Forest plots of linear dose–response trends with pooled estimates from random-effects meta-analysis per 100mg/day caffeine intake for low 
birth weight (A) and small for gestational age (C). B,D: Summary nonlinear dose–response curves from multivariate random effects meta-
analysis of restricted cubic spline curves for low birth weight (B) and small for gestational age (D), using zero intake as the reference intake. 
Tickmarks on the horizontal axis indicate the location of category medians, means, or midpoints for included studies. 
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